Check-Cap Ltd. (CHEK)
- Previous Close
0.6688 - Open
0.6373 - Bid --
- Ask --
- Day's Range
0.6372 - 0.6688 - 52 Week Range
0.5600 - 3.0400 - Volume
13,360 - Avg. Volume
164,501 - Market Cap (intraday)
3.913M - Beta (5Y Monthly) -0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1400 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
www.check-cap.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CHEK
View MorePerformance Overview: CHEK
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHEK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHEK
View MoreValuation Measures
Market Cap
3.91M
Enterprise Value
-20.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.21%
Return on Equity (ttm)
-53.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.56M
Diluted EPS (ttm)
-2.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
17.82M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.49M